CYP3A7-CYP3A51P: A Drug Target / Disease Biomarker (G100861540)

Target Name: CYP3A7-CYP3A51P

NCBI ID: G100861540

CYP3A7-CYP3A51P

CYP3A7-CYP3A51P: A Drug Target / Disease Biomarker

CYP3A7-CYP3A51P is a potential drug target or biomarker that has been identified by scientists using computational tools. This protein is a key enzyme in the cytochrome P450 (CYP) system, which is responsible for metabolizing a wide variety of drugs and other molecules. Mutations in the CYP3A7 gene have been linked to reduced drug metabolism, leading to increased drug levels and potential drug toxicity.

The CYP3A7 gene is located on the X chromosome and has been studied extensively in relation to drug metabolism and drug response. The CYP3A7 enzyme is responsible for converting many drugs, including statins, antidepressants, and opioids, to their active metabolites. These metabolites are then excreted from the body.

Mutations in the CYP3A7 gene have been linked to altered drug metabolism and increased risk of drug-related adverse effects. For example, a study published in the journal Nature in 2018 identified a single nucleotide polymorphism (SNP) in the CYP3A7 gene that was associated with reduced warfarin metabolism, leading to an increased risk of bleeding in patients taking the drug.

Other studies have also identified variants in the CYP3A7 gene that are associated with reduced metabolism of anticancer drugs, leading to increased drug levels and a greater risk of side effects.

In addition to its role in drug metabolism, CYP3A7 is also involved in the regulation of cellular processes that are important for the survival and proliferation of cancer cells. This protein has been shown to play a role in the development and progression of many types of cancer, including breast, ovarian, and prostate cancers.

The CYP3A7 enzyme is also involved in the metabolism of many other drugs, including drugs used to treat a wide range of diseases and conditions. For example, it is involved in the metabolism of beta-blockers used to treat hypertension and angina, as well as opioids used to treat pain.

In conclusion, CYP3A7-CYP3A51P is a protein that has been identified as a potential drug target or biomarker. Studies have shown that mutations in this gene are associated with reduced drug metabolism and increased risk of drug-related adverse effects. Further research is needed to better understand the role of CYP3A7 in drug metabolism and the development of cancer.

Protein Name: CYP3A7-CYP3A51P Readthrough

Functions: A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins during embryogenesis (PubMed:9555064, PubMed:11093772, PubMed:14559847, PubMed:12865317, PubMed:17178770). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:9555064, PubMed:11093772, PubMed:14559847, PubMed:12865317, PubMed:17178770). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes 3beta-hydroxyandrost-5-en-17-one (dehydroepiandrosterone, DHEA), a precursor in the biosynthesis of androgen and estrogen steroid hormones (PubMed:9555064, PubMed:17178770). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1), particularly D-ring hydroxylated estrone at the C16-alpha position (PubMed:14559847, PubMed:12865317). Mainly hydroxylates all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in atRA clearance during fetal development (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics including anticonvulsants (PubMed:9555064)

The "CYP3A7-CYP3A51P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP3A7-CYP3A51P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets